William Blair Issues Pessimistic Outlook for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - William Blair decreased their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a report issued on Monday, July 14th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will earn $16.17 per share for the year, down from their previous forecast of $16.20. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals' FY2026 earnings at $18.39 EPS.

A number of other research firms have also commented on VRTX. Scotiabank dropped their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. JPMorgan Chase & Co. raised their price objective on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a research note on Monday. Erste Group Bank cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Finally, Morgan Stanley dropped their target price on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a report on Friday, June 20th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $511.71.

Vertex Pharmaceuticals Stock Up 0.1%

Vertex Pharmaceuticals stock traded up $0.33 during mid-day trading on Wednesday, hitting $463.60. The company had a trading volume of 308,342 shares, compared to its average volume of 1,418,275. The stock has a market cap of $119.05 billion, a price-to-earnings ratio of -118.50 and a beta of 0.41. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The business has a fifty day moving average of $448.80 and a 200 day moving average of $462.07.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. During the same quarter in the previous year, the business posted $4.76 EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Capital World Investors increased its position in Vertex Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock worth $11,406,667,000 after buying an additional 1,514,993 shares during the period. Vanguard Group Inc. raised its stake in Vertex Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company's stock valued at $11,388,985,000 after purchasing an additional 232,873 shares during the last quarter. Capital Research Global Investors boosted its holdings in Vertex Pharmaceuticals by 15.8% in the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after purchasing an additional 1,426,746 shares during the period. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 23.3% in the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock worth $2,382,407,000 after purchasing an additional 1,117,214 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 17.2% during the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company's stock worth $2,454,373,000 after purchasing an additional 744,680 shares during the period. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.